Virtual Library

Start Your Search

Y. Zhang



Author of

  • +

    Poster Display session (Friday) (ID 65)

    • Event: ELCC 2018
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
    • +

      174P - Aprepitant, palonosetron and dexamethasone proved effective to prevent chemotherapy-related nausea and vomiting in lung cancer (ID 378)

      12:30 - 13:00  |  Presenting Author(s): Y. Zhang

      • Abstract

      Background:
      This study aimed to determine the antiemetic efficacy and safety of aprepitant, palonosetron and dexamethasone in patients with locally advanced or metastatic LC receiving one day full dose cisplatin-based combination chemotherapy (75 mg/m[2]).

      Methods:
      In this open-label, single-arm, single-centre study, 122 patients were enrolled as treatment group, and the antiemetic therapy consisted of palonosetron 0.75 mg on day 1, aprepitant 125 mg on day 1 and 80 mg on days 2–3 and dexamethasone 15 mg on days 1–3. With following, 125 patients were chosen as control group using Propensity Score Matching. The percentage of patients, who received rescue antiemetic medication, with metoclopramide included, was set as the primary endpoint. The secondary endpoints were complete response (CR; no vomiting/retching or rescue medication) in the overall period (0–120 h), and the rate of nausea and vomiting in all the patients who has already been suffered with nausea and vomiting without using aprepitant before. The incidence and severity of nausea were assessed on the basis of the Common Terminology Criteria for Adverse Events v4.03 and a subjective rating scale completed by patients.

      Results:
      There was no difference between two groups with personal characteristics. The percentage of patients who received rescue antiemetic medication (metoclopramide) in treatment group (n = 18) and control group (n = 39) were 14.8% and 37.1% (p < 0.05) respectively. The cumulative occurrence rate of vomiting for all chemotherapy cycles in treatment group and control group were 90.63% and 78.93% (p < 0.05). There was no difference between two groups with the cumulative occurrence rate of nausea for all chemotherapy cycles 69.79% and 73.03% (p > 0.05) respectively. After using aprepitant, the rate of nausea and vomiting were decreased to 37.5% (N = 6, p < 0.05) and 25% (N = 4, p < 0.05) in all the patients who has already been suffered with nausea and vomiting (100%, N = 16) without using aprepitant before. There was no drug related intolerance side effects.

      Conclusions:
      The combination antiemetic therapy was effective and well-tolerated in patients with locally advanced or metastatic LC receiving 1-day full dose cisplatin-based combination chemotherapy.

      Clinical trial identification:
      NCT02161991

      Legal entity responsible for the study:
      Yongchang Zhang

      Funding:
      Has not received any funding

      Disclosure:
      All authors have declared no conflicts of interest.